Skip to main content

Table 1 Patient characteristics

From: Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia

  CKD stage 3 (n = 1039) CKD stage 4 (n = 834) Dialysis (n = 1025) Total (n = 2898)
Sex, n (%)
 Female 411 (40) 343 (41) 410 (40) 1164 (40)
 Male 628 (60) 491 (59) 615 (60) 1734 (60)
Age, years
 Mean ± SD 63.4 ± 14.7 66.9 ± 14.5 61.5 ± 15.4 63.7 ± 15.1
 ≥65, n (%) 548 (53) 535 (64) 490 (48) 1573 (54)
Body mass index, kg/m2
 Mean ± SD 26.8 ± 4.7 27.0 ± 5.3 25.7 ± 4.9 26.5 ± 5.0
 ≥30, n (%) 210 (20) 178 (21) 155 (15) 543 (19)
 ˂ 30, n (%) 792 (76) 624 (75) 822 (80) 2238 (77)
 Missing 37 (4) 32 (4) 48 (5) 117 (4)
Anaemia status, n (%)
 Anaemic 453 (44) 633 (76) 887 (87) 1973 (68)
 Non-anaemic 479 (46) 177 (21) 84 (8) 740 (26)
 Missing 107 (10) 24 (3) 54 (5) 185 (6)
ESA and/or iron use, n (%) 197 (19) 420 (50) 801 (78) 1418 (49)
Country, n (%)
 France 206 (20) 177 (21) 190 (19) 573 (20)
 Germany 238 (23) 168 (20) 306 (30) 712 (25)
 Italy 214 (21) 161 (19) 190 (19) 565 (20)
 Spain 232 (22) 182 (22) 190 (19) 604 (21)
 UK 149 (14) 146 (18) 149 (15) 149 (15)
Comorbidities, n (%)
 Hypertension 903 (87) 741 (89) 725 (71) 2369 (82)
 SHPT 256 (25) 476 (57) 688 (67) 1420 (49)
 Type 2 diabetes 457 (44) 355 (43) 335 (33) 1147 (40)
 Dyslipidaemia 448 (43) 365 (44) 335 (33) 1148 (40)
Employment status, n (%)
 Employed a 288 (28) 142 (17) 199 (19) 629 (22)
 Retired 535 (51) 511 (61) 539 (53) 1585 (55)
 Other b 216 (21) 181 (22) 287 (28) 684 (24)
  1. Abbreviations: CKD chronic kidney disease, ESA erythropoiesis stimulating agent, SD standard deviation, SHPT secondary hyperparathyroidism
  2. a Full-time, part-time, or self-employed
  3. b Unemployed, homemaker, student, other